A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas : a Southwest oncology group study

Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily x 5, every 14 days, at a starting dose of 150 micrograms/m2/day....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunotherapy 1991-10, Vol.10 (5), p.376-378
Hauptverfasser:	BROWN, T. D, GOODMAN, P, FLEMING, T, MACDONALD, J. S, HERSH, E. M, BRAUN, T. J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - therapy Adult Aged Antineoplastic agents Biological and medical sciences Drug Evaluation Female Humans Immunotherapy Male Medical sciences Middle Aged Pancreatic Neoplasms - therapy Pharmacology. Drug treatments Recombinant Proteins - therapeutic use Tumor Necrosis Factor-alpha - adverse effects Tumor Necrosis Factor-alpha - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!